18 NOV 2021
14:30 CET

The ABC of ADCs

The ABC of ADCs



About event

Antibody drug conjugates (ADCs) have the potential to revolutionize conventional cancer treatment. They comprise of monoclonal antibodies that selectively deliver potent cytotoxic drugs. Each component of the ADC must be optimized to fully realize the goal of a targeted therapy with improved efficacy and tolerability. Advancements over the past several decades have led to a new generation of ADCs with balanced stability and highly potent cytotoxic agents. Although challenges remain, recent clinical successes have generated intense interest in this therapeutic class. World BI’s The ABC of ADCs discusses the characterization challenges of these ADCs and also their role in targeted tumor therapy.



Enhance Engagement


Data-Driven Approach


Can Be Tracked Easily


Real-Time Customizations


Cross Country Networking


Optimized Return on Investment

Speakers

Meet our Professionals



Shruthi

Shruthi Bharadwaj, Ph.D

Strategic and Technical Advisor Chief Data and AI Office

Novartis

Rajkumar

Rajkumar Ganesan

Director – Antibody Engineering (Bispecifics and CAR-T)

The Janssen Pharmaceutical Companies of Johnson & Johnson

Tomi

Tomi Sawyer

Chief Drug Hunter & President

Maestro Therapeutics

Sara

Sara Colombetti

Global Head of Oncology Discovery Pharmacology

Roche Innovation Center Zurich

Namshik

Namshik Han, PhD

Head of Artificial Intelligence

Milner Therapeutics Institute University of Cambridge

Schedule

Vast number of different speeches
and activities



Newsletter Sign Up

No Spam - Only latest news, price and activity updates

Who will attend

Delegates Will Include VPs, Global Heads, Directors and Managers.



Chief Scientific Officers
Research and Development
Chief Executive Officers
Corporate Development

Register to Event now!



Location

  • WorldBI, Office 7, 35-37 Ludgate Hill, London. EC4M 7JN
  • info@worldbigroup.com
  • 00 44 (0) 20 3129 8222
  • 10:00 - 18:00